Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154257 | 0.81 | MAPK1 (0.45) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL20877673 | 0.77 | MAPK1 (0.41) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL21107981 | 0.77 | MAPK1 (0.41) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL20877672 | 0.77 | MAPK1 (0.41) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL2600306 | 0.74 | MAPK1 (0.52) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL29591678 | 0.74 | MAPK1 (0.52) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL20812687 | 0.71 | MAPK1 (0.49) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL6362399 | 0.70 | MAPK1 (0.52) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL5558970 | 0.70 | HPGD (0.51) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL21931839 | 0.70 | GPR3 (0.38) | MAPK1HPGDTSHRALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293775-B2 | Benzoxazolone derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2012-10-23 | — | — | US | disclosed |
| EP-1756071-B1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2009-08-26 | — | — | EP | disclosed |
| US-20070299118-A1 | Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses | UCB, S.A. (BE) | 2007-12-27 | — | — | US | disclosed |
| EP-1756071-A1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118561-A1 | BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2005-12-15 | — | — | WO | disclosed |
| EP-0841330-B1 | Aminomethyl heterocyclic derivatives, process of their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2001-06-27 | — | — | EP | disclosed |
| EP-0673933-B1 | Aminoalkyl benzoxazolinones and benzothiazolinones process for their preparation and compositions containing them | ADIR (FR) | 2000-11-08 | — | — | EP | disclosed |
| EP-0673933-B1 | Aminoalkyl benzoxazolinones and benzothiazolinones process for their preparation and compositions containing them | ADIR (FR) | 2000-11-08 | — | — | EP | disclosed |
| CN-1055924-C | Novel aminoalkyl benzoxazolinones and benzothiazolinones process for their preparation and the pharmaceutical compositions which contain them | ADIR (FR) | 2000-08-30 | — | — | CN | disclosed |
| US-5688820-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | ADIR ET COMPAGNIE (FR) | 1997-11-18 | — | — | US | disclosed |
| US-5688820-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | ADIR ET COMPAGNIE (FR) | 1997-11-18 | — | — | US | disclosed |
| US-5688811-A | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | ADIR ET COMPAGNIE (FR) | 1997-11-18 | — | — | US | disclosed |
| US-5688811-A | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | ADIR ET COMPAGNIE (FR) | 1997-11-18 | — | — | US | disclosed |
| US-5534511-A | AFFINITY FOR SIGMA RECEPTORS, ANTIINFLAMMATORY, TREATMENT OF ARTHRITIS | ADIR ET COMPAGNIE (FR) | 1996-07-09 | — | — | US | disclosed |
| US-5534511-A | AFFINITY FOR SIGMA RECEPTORS, ANTIINFLAMMATORY, TREATMENT OF ARTHRITIS | ADIR ET COMPAGNIE (FR) | 1996-07-09 | — | — | US | disclosed |
| CN-1112114-A | Novel aminoalkyl benzoxazolinones and benzothiazolinones process for their preparation and the pharmaceutical compositions which contain them | ADIR (FR) | 1995-11-22 | — | — | CN | disclosed |
| CN-1112114-A | Novel aminoalkyl benzoxazolinones and benzothiazolinones process for their preparation and the pharmaceutical compositions which contain them | ADIR (FR) | 1995-11-22 | — | — | CN | disclosed |
| EP-0673933-A1 | Aminoalkyl benzoxazolinones and benzothiazolinones process for their preparation and compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-09-27 | — | — | EP | disclosed |
| EP-0673933-A1 | Aminoalkyl benzoxazolinones and benzothiazolinones process for their preparation and compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299118-A1 | Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses | PARK7, SNCA, GABRA5 | MAPK1 3250/4885HPGD 232/4885TSHR 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.